Trial Profile
A Double-Blind Randomised Placebo-Controlled Phase I/IIa Dose Titration Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine up to 30 mg vs Placebo BID in Subjects With Urinary Incontinence
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Litoxetine (Primary)
- Indications Urinary incontinence
- Focus Adverse reactions
- Sponsors IXALTIS
- 26 Jul 2020 Results presented at the 35th Congress of the European Association of Urology
- 08 Aug 2019 Status changed from active, no longer recruiting to completed.
- 25 Feb 2019 Planned primary completion date changed from 30 Jan 2019 to 28 Feb 2019.